We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+20.65%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$330M
AUM Growth
+$6.54M
Cap. Flow
+$8M
Cap. Flow %
2.43%
Top 10 Hldgs %
38.17%
Holding
104
New
22
Increased
33
Reduced
18
Closed
24
Avg Time Held Equity + Options
3 quarters
Top 10 Avg Time Held Equity + Options
0.7 quarters
Top 20 Avg Time Held Equity + Options
1.3 quarters
Avg Time Held Equity only
3.4 quarters
Top 10 Avg Time Held Equity only
0.8 quarters
Top 20 Avg Time Held Equity only
1.6 quarters

Top Buys

Rank Stock Value
1
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$17.8M
2
URGN icon
UroGen Pharma
URGN
+$8.17M
3
MRSN icon
Mersana Therapeutics
MRSN
+$7.61M
4
GOSS icon
Gossamer Bio
GOSS
+$7.06M
5
CBAY icon
Cymabay Therapeutics
CBAY
+$5.7M

Top Sells

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$10.3M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$10.2M
3
AKRO icon
Akero Therapeutics
AKRO
+$9.78M
4
KRYS icon
Krystal Biotech
KRYS
+$5.78M
5
ETNB icon
89bio
ETNB
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.31%
2 Miscellaneous 18.62%
3 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$21.9M 6.64%
+300,000
New +$24M
2023 Q3
0 quarters
IMGN icon
2
DELISTED
Immunogen Inc
IMGN
$20.7M 6.29%
1,307,435
-112,565
-8% -$1.87M
2020 Q4
11 quarters
MORF icon
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$13.5M 4.1%
590,829
+338,520
+134% +$17.8M
2020 Q4
11 quarters
MRUS icon
4
DELISTED
Merus
MRUS
$11.8M 3.57%
500,000
-89,255
-15% -$2.16M
2021 Q1
10 quarters
SLNO icon
5
DELISTED
Soleno Therapeutics
SLNO
$10.9M 3.31%
+370,000
New +$2.24M
2023 Q3
0 quarters
ITCI icon
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.9M 3.3%
208,730
+10,007
+5% +$583K
2020 Q4
11 quarters
AKRO icon
7
CALL
DELISTED
Akero Therapeutics
AKRO
$10.1M 3.07%
200,000
-36,500
-15% -$1.7M
2023 Q2
1 quarter
CBAY icon
8
DELISTED
Cymabay Therapeutics
CBAY
$8.8M 2.67%
590,000
+430,000
+269% +$5.7M
2023 Q2
1 quarter
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.71M 2.64%
200,000
+108,787
+119% +$3.88M
2023 Q2
1 quarter
PSTX icon
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$8.49M 2.57%
3,567,985
+622,037
+21% +$1.3M
2021 Q4
7 quarters
KRYS icon
11
Krystal Biotech
KRYS
$9.51B
$8.3M 2.52%
71,531
-47,410
-40% -$5.78M
2021 Q4
7 quarters
BIIB icon
12
Biogen
BIIB
$33.8B
$7.21M 2.19%
28,069
+1,215
+5% +$325K
2022 Q4
3 quarters
URGN icon
13
UroGen Pharma
URGN
$1.87B
$7.13M 2.16%
+508,883
New +$8.17M
2023 Q3
0 quarters
UTHR icon
14
United Therapeutics
UTHR
$23.3B
$7.1M 2.15%
31,424
+1,395
+5% +$321K
2020 Q4
11 quarters
PRAX icon
15
Praxis Precision Medicines
PRAX
$6.79B
$7.04M 2.14%
274,528
+42,784
+18% +$809K
2023 Q2
1 quarter
ORIC icon
16
Oric Pharmaceuticals
ORIC
$1.17B
$6.8M 2.06%
1,123,345
-327,477
-23% -$2.68M
2022 Q2
5 quarters
CRNX icon
17
DELISTED
Crinetics Pharmaceuticals
CRNX
$6.54M 1.98%
+220,000
New +$4.53M
2023 Q3
0 quarters
MRTX
18
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.53M 1.98%
150,000
– –
2023 Q2
1 quarter
COGT icon
19
Cogent Biosciences
COGT
$4.87B
$6.35M 1.93%
651,372
+31,372
+5% +$372K
2020 Q4
11 quarters
MRSN icon
20
DELISTED
Mersana Therapeutics
MRSN
$6.35M 1.93%
200,000
+160,000
+400% +$7.61M
2022 Q2
5 quarters
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$5.96B
$5.97M 1.81%
260,537
+144,369
+124% +$3.23M
2023 Q2
1 quarter
MGNX icon
22
MacroGenics
MGNX
$218M
$5.89M 1.79%
1,264,158
+48,483
+4% +$241K
2022 Q3
4 quarters
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.06B
$5.61M 1.7%
791,671
+30,767
+4% +$221K
2022 Q1
6 quarters
NVO icon
24
Novo Nordisk
NVO
$168B
$5.46M 1.65%
+60,000
New +$5.29M
2023 Q3
0 quarters
AKRO icon
25
PUT
DELISTED
Akero Therapeutics
AKRO
$5.39M 1.63%
+106,600
New +$4.96M
2023 Q3
0 quarters
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Silverarc Capital Management held 104 positions worth $330M, up 2% from $323M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management's Q3 2023 filing shows 22 new, 33 increased, 18 reduced and 24 closed positions. Its largest new stake was UroGen Pharma: 508,883 shares worth $7.13M. The largest sale was Schrodinger, an estimated $10.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Silverarc Capital Management's largest Q3 2023 buy was UroGen Pharma: 508,883 shares worth $7.13M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q3 2023, an estimated $17.8M increase.
  • Silverarc Capital Management's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $10.3M.
  • Silverarc Capital Management fully exited MoonLake Immunotherapeutics in Q3 2023, selling an estimated $10.2M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $330M portfolio in Q3 2023.
  • Silverarc Capital Management opened 22 new positions and closed 24 in Q3 2023.
  • Silverarc Capital Management's portfolio value rose 2% quarter-over-quarter to $330M.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.